233 related articles for article (PubMed ID: 26377682)
1. Occurrence of DNET and other brain tumors in Noonan syndrome warrants caution with growth hormone therapy.
McWilliams GD; SantaCruz K; Hart B; Clericuzio C
Am J Med Genet A; 2016 Jan; 170A(1):195-201. PubMed ID: 26377682
[TBL] [Abstract][Full Text] [Related]
2. Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature.
Siegfried A; Cances C; Denuelle M; Loukh N; Tauber M; Cavé H; Delisle MB
Am J Med Genet A; 2017 Apr; 173(4):1061-1065. PubMed ID: 28328117
[TBL] [Abstract][Full Text] [Related]
3. Response to growth hormone in short children with Noonan syndrome: correlation to genotype.
Binder G
Horm Res; 2009 Dec; 72 Suppl 2():52-6. PubMed ID: 20029239
[TBL] [Abstract][Full Text] [Related]
4. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.
Noordam C; Peer PG; Francois I; De Schepper J; van den Burgt I; Otten BJ
Eur J Endocrinol; 2008 Sep; 159(3):203-8. PubMed ID: 18562489
[TBL] [Abstract][Full Text] [Related]
5. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.
Ferreira LV; Souza SA; Arnhold IJ; Mendonca BB; Jorge AA
J Clin Endocrinol Metab; 2005 Sep; 90(9):5156-60. PubMed ID: 15956085
[TBL] [Abstract][Full Text] [Related]
6. Noonan syndrome: growth to growth hormone - the experience of observational studies.
Ranke MB
Horm Res; 2009 Dec; 72 Suppl 2():36-40. PubMed ID: 20029235
[TBL] [Abstract][Full Text] [Related]
7. GH therapy in Noonan syndrome: Review of final height data.
Dahlgren J
Horm Res; 2009 Dec; 72 Suppl 2():46-8. PubMed ID: 20029237
[TBL] [Abstract][Full Text] [Related]
8. Occurrence of high-grade glioma in Noonan syndrome: Report of two cases.
El-Ayadi M; Ansari M; Kühnöl CD; Bendel A; Sturm D; Pietsch T; Kramm CM; von Bueren AO
Pediatr Blood Cancer; 2019 May; 66(5):e27625. PubMed ID: 30693642
[TBL] [Abstract][Full Text] [Related]
9. Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 gene mutation.
Choi JH; Lee BH; Jung CW; Kim YM; Jin HY; Kim JM; Kim GH; Hwang JS; Yang SW; Lee J; Yoo HW
Horm Res Paediatr; 2012; 77(6):388-93. PubMed ID: 22777296
[TBL] [Abstract][Full Text] [Related]
10. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome.
Binder G; Neuer K; Ranke MB; Wittekindt NE
J Clin Endocrinol Metab; 2005 Sep; 90(9):5377-81. PubMed ID: 15985475
[TBL] [Abstract][Full Text] [Related]
11. [Noonan syndrome: from phenotype to growth hormone therapy].
Malaquias AC; Ferreira LV; Souza SC; Arnhold IJ; Mendonça BB; Jorge AA
Arq Bras Endocrinol Metabol; 2008 Jul; 52(5):800-8. PubMed ID: 18797587
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone and the heart in Noonan syndrome.
Noordam C
Horm Res; 2009 Dec; 72 Suppl 2():49-51. PubMed ID: 20029238
[TBL] [Abstract][Full Text] [Related]
13. IGF-I generation test in prepubertal children with Noonan syndrome due to mutations in the PTPN11 gene.
Bertelloni S; Baroncelli GI; Dati E; Ghione S; Baldinotti F; Toschi B; Simi P
Hormones (Athens); 2013; 12(1):86-92. PubMed ID: 23624134
[TBL] [Abstract][Full Text] [Related]
14. Atypical granular cell tumor occurring in an individual with Noonan syndrome treated with growth hormone.
Moos D; Droitcourt C; Rancherevince D; Marec Berard P; Skowron F
Pediatr Dermatol; 2012; 29(5):665-6. PubMed ID: 22329457
[TBL] [Abstract][Full Text] [Related]
15. Chronic pain in Noonan Syndrome: A previously unreported but common symptom.
Vegunta S; Cotugno R; Williamson A; Grebe TA
Am J Med Genet A; 2015 Dec; 167A(12):2998-3005. PubMed ID: 26297936
[TBL] [Abstract][Full Text] [Related]
16. [Phenotype variability in Noonan syndrome patients with and without PTPN11 mutation].
Ferreira LV; Souza SA; Montenegro LR; Arnhold IJ; Pasqualini T; Heinrich JJ; Keselman AC; Mendonça BB; Jorge AA
Arq Bras Endocrinol Metabol; 2007 Apr; 51(3):450-6. PubMed ID: 17546245
[TBL] [Abstract][Full Text] [Related]
17. Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation.
Jongmans MC; van der Burgt I; Hoogerbrugge PM; Noordam K; Yntema HG; Nillesen WM; Kuiper RP; Ligtenberg MJ; van Kessel AG; van Krieken JH; Kiemeney LA; Hoogerbrugge N
Eur J Hum Genet; 2011 Aug; 19(8):870-4. PubMed ID: 21407260
[TBL] [Abstract][Full Text] [Related]
18. Inside the Noonan "universe": Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns.
Stagi S; Ferrari V; Ferrari M; Priolo M; Tartaglia M
Front Endocrinol (Lausanne); 2022; 13():951331. PubMed ID: 36060964
[TBL] [Abstract][Full Text] [Related]
19. Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency.
Zavras N; Meazza C; Pilotta A; Gertosio C; Pagani S; Tinelli C; Bozzola M
Ital J Pediatr; 2015 Oct; 41():71. PubMed ID: 26444854
[TBL] [Abstract][Full Text] [Related]
20. Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations.
Athota JP; Bhat M; Nampoothiri S; Gowrishankar K; Narayanachar SG; Puttamallesh V; Farooque MO; Shetty S
BMC Med Genet; 2020 Mar; 21(1):50. PubMed ID: 32164556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
